TRIM28 Selective Nanobody Reduces Glioblastoma Stem Cell Invasion.
TRIM28
cell invasion
glioblastoma
glioblastoma stem cells
nanobody
transcription factor
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
25 Aug 2021
25 Aug 2021
Historique:
received:
06
07
2021
revised:
22
08
2021
accepted:
23
08
2021
entrez:
10
9
2021
pubmed:
11
9
2021
medline:
29
9
2021
Statut:
epublish
Résumé
Glioblastoma (GB), is the most common and aggressive malignant primary brain tumour in adults. Intra- and inter-tumour heterogeneity, infiltrative GB cell invasion and presence of therapy-resistant GB stem cells (GSCs) represent major obstacles to favourable prognosis and poor therapy response. Identifying the biomarkers of the most aggressive tumour cells and their more efficient targeting strategies are; therefore, crucial. Recently, transcription factor TRIM28 has been identified as a GB biomarker and, in this study, we have shown high expression of TRIM28 in GB and in low grade gliomas as well as higher expression in GSCs vs. differentiated GB cells, although in both cases not significant. We demonstrated significant in vitro inhibition of GB cells and GSCs invasiveness and spread in zebrafish brains in vivo by anti-TRIM28 selective nanobody NB237. TRIM28 was also enriched in GB (tumour) core and associated with the expression of stem cell genes, but was not prognostic for overall survival. However, based on the above results, we conclude that TRIM28 nanobody NB237 offers a new opportunity as a GB therapeutic tool.
Identifiants
pubmed: 34500575
pii: molecules26175141
doi: 10.3390/molecules26175141
pmc: PMC8434287
pii:
doi:
Substances chimiques
TRIM28 protein, human
EC 2.3.2.27
Tripartite Motif-Containing Protein 28
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : Grant Program P1-0245 to TLT
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : post-doctoral projects Z3-1870 to BB
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : post-doctoral projects Z3-1869 to IJ
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : post-doctoral projects Z3-2649 to NŠ
Organisme : European Program of Cross-Border Cooperation for Slovenia-Italy Interreg
ID : TRANS-GLIOMA to TLT, RK
Références
Front Immunol. 2021 Mar 09;12:632687
pubmed: 33767701
Aging (Albany NY). 2020 Oct 22;12(20):20308-20331
pubmed: 33091876
Int J Cancer. 2012 Oct 15;131(8):1779-89
pubmed: 22287159
Neuroscience. 2017 Jul 25;356:35-43
pubmed: 28526577
J Neurochem. 2005 Nov;95(4):1201-14
pubmed: 16271053
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Cancer Immunol Immunother. 2007 Mar;56(3):303-317
pubmed: 16738850
Onco Targets Ther. 2019 Jan 03;12:397-404
pubmed: 30655676
Nature. 2012 Aug 23;488(7412):522-6
pubmed: 22854781
PLoS One. 2014 Nov 24;9(11):e113688
pubmed: 25419715
Cytometry A. 2016 Apr;89(4):365-75
pubmed: 26671187
Drugs. 2018 Oct;78(15):1639-1642
pubmed: 30298461
Front Cell Dev Biol. 2021 Feb 11;9:616551
pubmed: 33644052
Nature. 1993 Jun 3;363(6428):446-8
pubmed: 8502296
Radiol Oncol. 2016 Mar 26;50(2):159-67
pubmed: 27247548
Methods Mol Biol. 2012;907:145-76
pubmed: 22907350
FASEB J. 2012 Oct;26(10):3969-79
pubmed: 22730440
Neuroscience. 2011 Sep 8;190:37-42
pubmed: 21683126
Plant Physiol. 2018 Sep;178(1):488-499
pubmed: 29934298
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Int J Mol Sci. 2017 Nov 18;18(11):
pubmed: 29156557
Mol Oncol. 2017 Mar;11(3):280-294
pubmed: 28100038
Cell Rep. 2019 Feb 12;26(7):1893-1905.e7
pubmed: 30759398
Cancers (Basel). 2010 Dec 15;2(4):2100-37
pubmed: 24281220
BMC Bioinformatics. 2017 May 25;18(1):276
pubmed: 28545393
Cancer Cell. 2017 Jul 10;32(1):42-56.e6
pubmed: 28697342
Neuro Oncol. 2018 May 18;20(6):776-787
pubmed: 29228370
Nat Chem. 2017 Aug;9(8):762-771
pubmed: 28754949
J Proteome Res. 2009 Feb;8(2):583-94
pubmed: 19086899
Nat Biotechnol. 2005 Sep;23(9):1126-36
pubmed: 16151406
BioDrugs. 2020 Feb;34(1):11-26
pubmed: 31686399
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Oncogenesis. 2017 Apr 10;6(4):e312
pubmed: 28394358
Ther Adv Med Oncol. 2020 Apr 28;12:1758835920915302
pubmed: 32426045
Cancer Epidemiol. 2013 Feb;37(1):71-8
pubmed: 22959342
Methods Mol Biol. 2012;907:109-22
pubmed: 22907348
J Histochem Cytochem. 2015 Oct;63(10):749-61
pubmed: 26109632
Cancer Res. 2015 Jan 15;75(2):344-55
pubmed: 25421577
Oncogene. 2017 Jan 26;36(4):570-584
pubmed: 27345406
Genes (Basel). 2017 Sep 06;8(9):
pubmed: 28878163
Mol Cell Biol. 2014 Jun;34(11):2075-91
pubmed: 24687849
Science. 2014 Jun 20;344(6190):1396-401
pubmed: 24925914
Semin Cancer Biol. 2020 Feb;60:262-273
pubmed: 31654711
Neuro Oncol. 2017 Jan;19(1):139-141
pubmed: 28031383
FASEB J. 2002 Feb;16(2):240-2
pubmed: 11772942
Br J Pharmacol. 2012 Apr;165(7):2341-53
pubmed: 22013955
Int J Mol Sci. 2020 Jun 12;21(12):
pubmed: 32545571
Cell. 2016 Jan 28;164(3):550-63
pubmed: 26824661
J Neurooncol. 2016 Jan;126(1):19-26
pubmed: 26476730
Oncogene. 2018 Jul;37(30):4110-4121
pubmed: 29706656
Annu Rev Biochem. 2013;82:775-97
pubmed: 23495938
Trends Biochem Sci. 2001 Apr;26(4):230-5
pubmed: 11295555
Neuro Oncol. 2010 May;12(5):508-16
pubmed: 20406901
Ann Surg Oncol. 2010 Mar;17(3):821-8
pubmed: 19898899
Cell Death Differ. 2021 Feb;28(2):522-537
pubmed: 33432111
Oncotarget. 2017 Jul 4;8(27):44141-44158
pubmed: 28498803
Acta Neuropathol. 2007 Nov;114(5):443-58
pubmed: 17805551
Int J Mol Sci. 2020 Mar 12;21(6):
pubmed: 32178267
Adv Exp Med Biol. 2012;770:59-76
pubmed: 23631000
Nat Commun. 2020 Sep 16;11(1):4660
pubmed: 32938908
Oncotarget. 2017 Apr 11;8(15):25482-25499
pubmed: 28424417
Nanomedicine (Lond). 2015 Jan;10(1):161-74
pubmed: 25597775
Nat Rev Cancer. 2011 Oct 07;11(11):792-804
pubmed: 21979307
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Genes Dev. 2015 Jun 15;29(12):1203-17
pubmed: 26109046